VRCA

0.601

13.37% 0.0709

Handel nachbörslich: .59 -0.011 -1.83%

Verrica Pharmaceuticals Inc (VRCA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.5301

Offen:

$0.543

24-Stunden-Volumen:

3.72M

Relative Volume:

10.55

Marktkapitalisierung:

$55.59M

Einnahmen:

$5.12M

Nettoeinkommen (Verlust:

$-67.00M

KGV:

-0.4088

EPS:

-1.47

Netto-Cashflow:

$-38.94M

1W Leistung:

+0.50%

1M Leistung:

+21.51%

6M Leistung:

-14.14%

1J Leistung:

-92.44%

1-Tages-Spanne:

$0.53

$0.6741

1-Wochen-Bereich:

$0.5226

$0.6741

52-Wochen-Spanne:

$0.3816

$8.98

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Firmenname

Verrica Pharmaceuticals Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

484-453-3300

Adresse

10 NORTH HIGH STREET, WEST CHESTER, PA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-11

Neueste SEC-Einreichungen

VRCA's Discussions on Twitter

Vergleichen Sie VRCA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VRCA Verrica Pharmaceuticals Inc	0.601	55.59M	5.12M	-67.00M	-38.94M	-1.47
VRTX Vertex Pharmaceuticals Inc	452.16	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	534.91	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.06	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.47	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.16	28.51B	3.81B	-644.79M	-669.77M	-6.24

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-06	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-11-05	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-07-25	Hochstufung	Needham	Hold → Buy
2023-03-22	Eingeleitet	Jefferies	Buy
2023-02-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-05-25	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-05-14	Eingeleitet	RBC Capital Mkts	Outperform
2020-12-24	Bestätigt	H.C. Wainwright	Buy
2020-07-15	Herabstufung	BofA Securities	Buy → Neutral
2020-06-30	Bestätigt	H.C. Wainwright	Buy
2020-06-24	Eingeleitet	Northland Capital	Outperform
2020-03-24	Eingeleitet	Needham	Buy
2019-02-21	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten

Jun 18, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest - Defense World

Jun 18, 2025

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results - Barchart.com

Jun 18, 2025

Jun 16, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages - Defense World

Jun 16, 2025

Jun 13, 2025

Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st

Jun 13, 2025

Jun 12, 2025

Verrica Pharmaceuticals amends credit agreement By Investing.com - Investing.com South Africa

Jun 12, 2025

Verrica Pharmaceuticals Amends Credit Agreement with OrbiMed - TipRanks

Jun 12, 2025

Verrica Pharmaceuticals amends credit agreement - Investing.com

Jun 12, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic? - Yahoo Finance

Jun 12, 2025

Jun 10, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% – Here’s Why - Defense World

Jun 10, 2025

Jun 05, 2025

Verrica Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 05, 2025

May 30, 2025

Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN

May 30, 2025

May 28, 2025

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - GlobeNewswire

May 28, 2025

Verrica Pharmaceuticals CEO Reveals Dermatology Pipeline Updates at Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 25, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen - Defense World

May 25, 2025

Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Target Price at $8.00 - Defense World

May 25, 2025

May 24, 2025

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline - MSN

May 24, 2025

May 22, 2025

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN

May 22, 2025

May 21, 2025

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail

May 21, 2025

May 20, 2025

Verrica Pharmaceuticals’ SWOT analysis: stock faces cash crunch amid YCANTH growth - Investing.com Canada

May 20, 2025

Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World

May 16, 2025

May 15, 2025

Verrica signals sustainable growth trajectory as YCANTH revenues surpass $3M and Phase 3 milestone looms - MSN

May 15, 2025

RBC Capital Reaffirms Their Hold Rating on Verrica Pharmaceuticals (VRCA) - The Globe and Mail

May 15, 2025

May 14, 2025

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update - MSN

May 14, 2025

Verrica Pharmaceuticals (VRCA) Sees Q1 Revenue Growth Driven by YCANTH - GuruFocus

May 14, 2025

Verrica Pharmaceuticals (VRCA) Receives Hold Rating from Needham - GuruFocus

May 14, 2025